Tiziana Life Sciences (TLSA) Accumulated Expenses (2018 - 2025)

Tiziana Life Sciences (TLSA) has reported Accumulated Expenses for 8 consecutive years, with $3.3 million the latest figure, recorded in Q4 2025.

• Quarterly Accumulated Expenses rose 99.21% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 99.21% YoY) and the FY2025 annual result came in at $3.3 million, up 99.21% from the prior year.
• Accumulated Expenses climbed to $3.3 million in Q4 2025 per TLSA's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for TLSA reached as high as $3.3 million in Q4 2025 and fell as low as $816000.0 in Q2 2023.
• A 5-year average of $1.7 million and a median of $1.6 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 66.15% — and 2025, when it soared 99.21%.
• Year by year, Accumulated Expenses stood at $900000.0 in 2021, then soared by 74.44% to $1.6 million in 2022, then surged by 43.31% to $2.2 million in 2023, then slipped by 26.67% to $1.6 million in 2024, then jumped by 99.21% to $3.3 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $3.3 million, $1.7 million, and $1.6 million for Q4 2025, Q2 2025, and Q4 2024 respectively.